Your browser is no longer supported. Please, upgrade your browser.
Settings
FOMX Foamix Pharmaceuticals Ltd. daily Stock Chart
FOMX [NASD]
Foamix Pharmaceuticals Ltd.
Index- P/E- EPS (ttm)-1.26 Insider Own1.00% Shs Outstand56.87M Perf Week11.76%
Market Cap183.69M Forward P/E- EPS next Y-1.38 Insider Trans-2.10% Shs Float56.87M Perf Month55.29%
Income-63.80M PEG- EPS next Q-0.38 Inst Own50.50% Short Float4.09% Perf Quarter31.30%
Sales2.00M P/S91.85 EPS this Y3.40% Inst Trans-7.37% Short Ratio3.94 Perf Half Y-9.27%
Book/sh1.11 P/B2.91 EPS next Y6.10% ROA-66.30% Target Price15.67 Perf Year-46.17%
Cash/sh1.22 P/C2.65 EPS next 5Y- ROE-76.00% 52W Range1.97 - 7.60 Perf YTD-10.03%
Dividend- P/FCF- EPS past 5Y- ROI-81.50% 52W High-57.50% Beta1.41
Dividend %- Quick Ratio5.10 Sales past 5Y20.70% Gross Margin- 52W Low63.96% ATR0.23
Employees81 Current Ratio5.10 Sales Q/Q- Oper. Margin- RSI (14)67.22 Volatility8.46% 8.89%
OptionableYes Debt/Eq0.00 EPS Q/Q24.90% Profit Margin- Rel Volume1.76 Prev Close2.97
ShortableYes LT Debt/Eq0.00 EarningsAug 07 AMC Payout- Avg Volume590.87K Price3.23
Recom1.80 SMA2025.07% SMA5029.67% SMA200-2.17% Volume1,021,176 Change8.75%
Jun-11-19Initiated Barclays Overweight $10
Dec-12-18Initiated BofA/Merrill Buy
Sep-12-18Reiterated H.C. Wainwright Buy $12 → $14
Dec-06-17Initiated Guggenheim Buy $8
Aug-24-17Initiated H.C. Wainwright Buy $12
Feb-15-17Initiated Credit Suisse Outperform $22
Apr-16-15Initiated Guggenheim Buy $14
Mar-16-15Reiterated Barclays Overweight $11 → $15
Nov-18-14Initiated Maxim Group Hold $38
Oct-13-14Initiated Oppenheimer Outperform $15
Aug-16-19 07:15PM  Edited Transcript of FOMX earnings conference call or presentation 8-Aug-19 12:30pm GMT Thomson Reuters StreetEvents +7.27%
Aug-13-19 09:09AM  This Latest Target Price On Foamix (FOMX) Stock Looks Positively Frothy TipRanks +14.93%
Aug-09-19 10:27AM  Bank of America Sees Over 350% Upside in Foamix (FOMX) Stock TipRanks +16.32%
Aug-05-19 08:02AM  Foamix Submits New Drug Application to U.S. FDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosacea PR Newswire
Jul-31-19 10:36AM  Will Foamix (FOMX) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-30-19 08:00AM  Foamix Announces $64 Million Capital Financing Investment by Perceptive Advisors and OrbiMed GlobeNewswire +9.81%
Jul-24-19 08:00AM  Foamix Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 8 GlobeNewswire
Jul-11-19 06:20AM  Do Directors Own Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Shares? Simply Wall St.
Jun-23-19 04:13PM  Is Foamix Pharmaceuticals Ltd (FOMX) A Good Stock To Buy? Insider Monkey
Jun-12-19 06:29AM  Barclays Has New Plays for Healthcare Fans SmarterAnalyst
Jun-04-19 08:00AM  Foamix Announces Publication of Phase 3 FMX101 Acne Study in Journal of American Academy of Dermatology GlobeNewswire
May-17-19 08:19AM  Edited Transcript of FOMX earnings conference call or presentation 8-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-15-19 06:55AM  Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now SmarterAnalyst
May-09-19 03:01PM  Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX): The Best Of Both Worlds Simply Wall St.
11:23AM  Foamix Pharmaceuticals (FOMX) Q1 2019 Earnings Call Transcript Motley Fool
May-07-19 06:05PM  Foamix (FOMX) Reports Q1 Loss, Misses Revenue Estimates Zacks -5.12%
05:03PM  Foamix: 1Q Earnings Snapshot Associated Press
04:21PM  Foamix Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
May-06-19 08:00AM  Foamix Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019 GlobeNewswire
Apr-30-19 10:32AM  Will Foamix (FOMX) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-29-19 08:00AM  Foamix to Present Late Breaking Data at the 77th Annual Meeting of the Society for Investigative Dermatology GlobeNewswire
Apr-24-19 08:00AM  Foamix Pharmaceuticals First Quarter 2019 Financial Results Conference Call & Webcast Scheduled for May 8 GlobeNewswire
Apr-11-19 12:14PM  This Small-Cap Biotech Stock Could Triple in 2019 GuruFocus.com
Apr-04-19 12:58PM  What Kind Of Share Price Volatility Should You Expect For Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)? Simply Wall St.
Apr-02-19 08:00AM  Foamix Announces Settlement of Litigation with Perrigo Relating to Finacea Foam GlobeNewswire
Mar-08-19 08:00AM  Foamix Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2019 GlobeNewswire +9.00%
Mar-07-19 12:46PM  Edited Transcript of FOMX earnings conference call or presentation 1-Mar-19 1:30pm GMT Thomson Reuters StreetEvents
08:00AM  Foamix Announces FDA Acceptance of New Drug Application for FMX101 Minocycline Foam for the Treatment of Moderate-to-Severe Acne GlobeNewswire
Mar-06-19 08:00AM  Foamix Pharmaceuticals to Present at the Cowen & Company 39th Annual Health Care Conference GlobeNewswire
Feb-28-19 04:01PM  Foamix Reports Fiscal Year 2018 Financial Results and Provides Corporate Update GlobeNewswire
Feb-27-19 11:50AM  How Many Insiders Bought Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Shares? Simply Wall St.
08:00AM  Foamix Announces Positive Results from Phase 3 Open-Label Safety Study Evaluating FMX103 Topical Minocycline Foam for Treatment up to One Year GlobeNewswire
Feb-26-19 08:00AM  Foamix -- with Late-Stage Candidates in Acne and Rosacea -- to Participate at American Academy of Dermatology Annual Meeting GlobeNewswire
Feb-21-19 10:31AM  Will Foamix (FOMX) Report Negative Earnings Next Week? What You Should Know Zacks
Feb-14-19 08:00AM  Foamix Pharmaceuticals Fourth Quarter Financial Results Conference Call & Webcast Scheduled for March 1 GlobeNewswire
Jan-23-19 08:00AM  Foamix Announces Appointment of Sharon Barbari to Board of Directors GlobeNewswire
Jan-22-19 11:38AM  Are Foamix Pharmaceuticals Ltd.s (NASDAQ:FOMX) Interest Costs Too High? Simply Wall St.
Dec-21-18 07:00AM  Foamix Submits New Drug Application to U.S. FDA Seeking Approval of FMX101 in Treatment of Moderate-to-Severe Acne GlobeNewswire -6.13%
Dec-16-18 10:16PM  Is Foamix Pharmaceuticals Ltd (FOMX) A Good Stock To Buy? Insider Monkey
Dec-14-18 12:49PM  Could Foamix Pharmaceuticals Ltd.s (NASDAQ:FOMX) Investor Composition Influence The Stock Price? Simply Wall St.
Dec-13-18 02:21AM  Edited Transcript of FOMX earnings conference call or presentation 9-May-18 12:30pm GMT Thomson Reuters StreetEvents
Nov-27-18 08:00AM  Foamix Announces Appointment of Matt Wiley as Chief Commercial Officer GlobeNewswire
Nov-20-18 08:29AM  The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings Benzinga
Nov-19-18 08:00AM  Foamix Announces Appointment of Anthony Bruno to Board of Directors GlobeNewswire -5.63%
Nov-16-18 11:48AM  Edited Transcript of FOMX earnings conference call or presentation 8-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Nov-13-18 07:55AM  Recent Analysis Shows WPX Energy, Verizon Communications, Innovative Industrial Properties, Foamix Pharmaceuticals, O2Micro International, and Investment Technology Group Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire -6.57%
Nov-07-18 07:50PM  Foamix (FOMX) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:05PM  Foamix Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
06:00AM  Foamix's treatment for common skin condition meets late-stage trial goals Reuters
06:00AM  Foamix Announces Positive Topline Results from Phase 3 Program Evaluating FMX103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea GlobeNewswire
Oct-29-18 08:49AM  Implied Volatility Surging for Foamix (FOMX) Stock Options Zacks
08:00AM  Foamix Pharmaceuticals Third Quarter Financial Results Conference Call & Webcast Scheduled for November 8 GlobeNewswire
Oct-22-18 12:26PM  Does Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Have A High Beta? Simply Wall St.
Oct-12-18 08:00AM  Foamix to Present Clinical Data From Study FX2017-22 at the Fall Clinical Dermatology Conference GlobeNewswire
Oct-01-18 08:00AM  Foamix Announces Additional Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne GlobeNewswire
Sep-26-18 08:00AM  Foamix Pharmaceuticals to Participate in the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-18-18 10:55AM  Foamix Announces Closing of its Follow-on Offering of Ordinary Shares and Full Exercise of its Option by the Underwriters GlobeNewswire -9.58%
Sep-13-18 07:06PM  Foamix Announces Pricing of its Follow-on Offering of Ordinary Shares GlobeNewswire
08:00AM  Today's Research Reports on Trending Tickers: Progenics Pharmaceuticals and Foamix Pharmaceuticals ACCESSWIRE
Sep-12-18 04:31PM  Foamix Announces Proposed Follow-on Offering of Ordinary Shares GlobeNewswire
02:15PM  Cannabis and Biotech Stock that could Explode ACCESSWIRE
09:58AM  Foamix's Acne Candidate Succeeds in Study, Shares Rally Zacks
08:34AM  Foamix stock surges 30% on positive late-stage results for acne medication MarketWatch
08:30AM  Foamix's stock rockets after successful trial results for acne treatment MarketWatch
08:26AM  The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt Benzinga
Sep-11-18 05:39PM  Foamix acne drug meets main goals in late-stage trial, shares surge Reuters
05:00PM  Foamix Announces Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne GlobeNewswire
Sep-07-18 11:54AM  Did An Insider Sell Their Shares In Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)? Simply Wall St.
Aug-21-18 08:39AM  Implied Volatility Surging for Foamix Pharmaceuticals (FOMX) Stock Options Zacks
Aug-08-18 07:40PM  Foamix (FOMX) Reports Q2 Loss, Lags Revenue Estimates Zacks
06:37PM  Foamix: 2Q Earnings Snapshot Associated Press
04:01PM  Foamix Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Aug-01-18 08:00AM  Foamix Pharmaceuticals to Announce Second Quarter Financial Results on August 8 GlobeNewswire
Jun-27-18 09:04AM  CORRECTING and REPLACING -- Foamix Announces Dosing of Last Patient in Phase 3 Rosacea Studies for Minocycline Foam FMX103 GlobeNewswire
Jun-14-18 08:00AM  Foamix Pharmaceuticals to Participate in the Cantor Dermatology & Aesthetics Summit GlobeNewswire
May-22-18 12:02PM  May Best Growth Stocks Simply Wall St.
May-09-18 07:39AM  With A -124.01% Earnings Drop, Did Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Really Underperform? Simply Wall St. +5.27%
05:03AM  Foamix: 1Q Earnings Snapshot Associated Press
May-08-18 05:04PM  Foamix Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
May-07-18 08:00AM  Foamix Announces Dosing of Last Patient in Third Phase 3 Acne Study for Minocycline Foam FMX101 GlobeNewswire
Apr-16-18 08:00AM  Foamix Announces $16 Million Investment by OrbiMed GlobeNewswire
Mar-12-18 12:02PM  Cheniere Energy Partners Holdings And Other Great Growth Stocks Simply Wall St.
Mar-08-18 08:00AM  Foamix Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2018 GlobeNewswire -5.80%
Mar-06-18 08:00AM  Foamix Pharmaceuticals to Present at the Cowen & Company 38th Annual Health Care Conference GlobeNewswire
Mar-01-18 12:10PM  Edited Transcript of FOMX earnings conference call or presentation 28-Feb-18 1:30pm GMT Thomson Reuters StreetEvents
Feb-28-18 08:00AM  Foamix Reports Fiscal Year 2017 Financial Results and Provides Corporate Update GlobeNewswire
06:30AM  Foamix Pharmaceuticals Ltd. to Host Earnings Call ACCESSWIRE
Feb-27-18 07:19AM  When Will Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Become Profitable? Simply Wall St.
Feb-13-18 08:00AM  Foamix Pharmaceuticals Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call & Webcast Scheduled for February 28 GlobeNewswire
Jan-04-18 08:00AM  Foamix Announces Positive Results from Phase 3 Open-Label Safety Extension Evaluating FMX-101 Topical Minocycline Foam for Treatment up to 1 Year GlobeNewswire +5.23%
Jan-03-18 08:00AM  Foamix Names Mr. David Domzalski as a Member of the Board of Foamix Pharmaceuticals GlobeNewswire
Dec-21-17 10:35AM  Allergan/Paratek's Acne Candidate NDA Filing Accepted by FDA Zacks
Nov-21-17 11:21AM  Edited Transcript of FOMX earnings conference call or presentation 15-Nov-17 1:30pm GMT Thomson Reuters StreetEvents
Nov-16-17 05:14AM  Foamix reports 3Q loss Associated Press
Nov-15-17 07:00AM  Foamix Reports Third Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
06:50AM  Foamix Pharmaceuticals Ltd. to Host Earnings Call ACCESSWIRE
Nov-14-17 06:39AM  Should You Buy Foamix Pharmaceuticals Ltd (FOMX)? Simply Wall St.
Nov-01-17 08:00AM  Foamix Pharmaceuticals Third Quarter Financial Results Conference Call & Webcast Scheduled for November 15, 2017 GlobeNewswire
Sep-18-17 01:20PM  Foamix Pharmaceuticals Ltd. :FOMX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 Capital Cube +7.49%
Sep-14-17 07:00AM  OWC Pharma Issues Chairman's Letter to Shareholders PR Newswire
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hirsch StanleyDirectorAug 13Option Exercise0.6260,00037,20060,000Aug 14 02:59 PM
KAZANCHYAN ANNADirectorJul 15Sale2.318081,86644,547Jul 17 04:40 PM
Harsch MutyaCLO and General CounselJul 01Sale2.356391,50251,969Jul 03 04:28 PM
Domzalski DavidCEOJul 01Sale2.353,3557,884211,240Jul 03 04:27 PM
Stuart IainChief Scientific OfficerJul 01Sale2.359512,23563,524Jul 03 04:26 PM
KAZANCHYAN ANNADirectorMay 20Sale2.6110,60027,66645,355May 20 06:35 PM
Harsch MutyaCLO and General CounselApr 01Sale3.752,5199,44652,608Apr 03 04:42 PM
Domzalski DavidCEOApr 01Sale3.755,09619,110214,595Apr 03 04:40 PM
Stuart IainChief Scientific OfficerApr 01Sale3.751,6966,36064,475Apr 03 04:38 PM
Wiley Matthew T.Chief Commercial OfficerMar 05Buy3.7613,44050,53463,440Mar 06 04:07 PM
Domzalski DavidCEODec 03Sale4.0568275146,409Dec 06 06:06 AM
Schwartz AharonDirectorNov 28Buy3.8812,20047,373112,200Dec 06 06:09 AM
Schwartz AharonDirectorNov 27Buy3.9250,000195,800100,000Dec 06 06:09 AM
Schwartz AharonDirectorNov 26Buy3.8950,000194,60050,000Dec 06 06:09 AM
Domzalski DavidCEONov 19Sale3.905,03619,640146,477Nov 20 04:07 PM
Howard Alvin DVP RegulatoryNov 19Sale3.903,37513,16338,414Nov 20 04:05 PM
Stuart IainSVP R&DNov 08Sale4.586833,12833,602Nov 13 06:16 AM
Domzalski DavidCEONov 08Sale4.582,0629,444151,513Nov 13 06:13 AM
Howard Alvin DVP RegulatoryOct 01Sale5.812341,36041,789Oct 02 05:22 PM
Elliott Russell P.VP Drug DevelopmentOct 01Sale5.8114282512,442Oct 02 05:20 PM
Domzalski DavidCEOOct 01Sale5.816013,492153,575Oct 02 05:18 PM
Domzalski DavidCEOSep 04Sale5.6767380154,176Sep 06 04:05 PM